MedTrace Logo

Dose Ranging Study of Recombinant Human Insulin-like Growth Factor I in Children With Hyperinsulinism

NCT00004699 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2015-03-25

No results posted yet for this study

Summary

OBJECTIVES:

I. Determine the dose of recombinant human insulin-like growth factor I that minimizes or decreases the need for exogenous glucose support without causing hypoglycemia.

Conditions

  • Hyperinsulinism

Interventions

DRUG

insulin-like growth factor I

Sponsors & Collaborators

Principal Investigators

  • Pinchas Cohen · Children's Hospital of Philadelphia

Study Design

Purpose
TREATMENT

Eligibility

Min Age
3 Weeks
Max Age
3 Months
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1995-08-31
Completion
1999-01-31

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00004699 on ClinicalTrials.gov